癌症腫瘤分析市場規模、佔有率、成長分析、按癌症類型、按生物標記類型、按技術、按方法、按應用、按地區 - 行業預測，2025 年至 2032 年

癌症腫瘤分析市場預計將從 2024 年的 134.4 億美元成長到 2032 年的 312 億美元，預測期內（2025-2032 年）的複合年成長率為 11.1%。

癌症發生率的上升以及生物標記在腫瘤分析中的應用增多，增強了全球癌症檢測和治療市場的發展。不斷增加的研究資金和技術進步正在推動癌症和腫瘤分析領域的發展。此外，個人化醫療和照護現場診斷的趨勢預計將在未來幾年為市場參與企業創造巨大的商機。 COVID-19 疫情最初擾亂了癌症檢測和診斷，但整體市場仍保持彈性。癌症/腫瘤分析領域（包括基因組學、蛋白質組學、表觀遺傳學和代謝體學）預計在預測期內將實現成長，其中基因組學預計最高複合年成長率為 19.7%，推動揭示與癌症復原力和進展相關的基因異常的創新。

目錄

介紹

• 調查目的
• 研究範圍
• 定義

調查方法

• 資訊採購
• 次要和主要資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分機會分析

市場動態及展望

• 市場概況
• 市場規模
• 市場動態
  • 促進因素和機會
  • 限制與挑戰
• 波特的分析

主要市場考察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 市場吸引力指數（2024 年）
• PESTEL 分析
• 總體經濟指標
• 價值鏈分析
• 定價分析

癌症腫瘤分析市場規模（按癌症類型）

• 市場概況
• 乳癌
• 肺癌
• 大腸直腸癌
• 攝護腺癌
• 黑色素瘤
• 其他癌症

癌症腫瘤分析市場規模（依生物標記類型）

• 市場概況
• 基因生物標記
• 蛋白質生物標記

癌症腫瘤分析市場規模（按技術）

• 市場概況
• 免疫檢測
• 次世代定序
• 聚合酵素鏈鎖反應
• 質譜分析
• 原位雜合技術
• 微陣列
• 其他

癌症腫瘤分析市場規模（依方法）

• 市場概況
• 基因組學
• 蛋白質體學
• 代謝體學
• 表觀遺傳學

癌症腫瘤分析市場規模（按應用）

• 市場概況
• 調查
• 生物標記發現
• 個人化醫療
• 臨床應用
• 診斷
• 預言
• 篩檢
• 治療和監測

癌症腫瘤分析市場規模

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前 5 家公司對比
• 主要企業市場定位（2024年）
• 主要市場參與者所採用的策略
• 近期市場趨勢
• 公司市場佔有率分析（2024 年）
• 主要企業簡介
  • 公司詳細資訊
  • 產品系列分析
  • 公司分部佔有率分析
  • 收益與前一年同期比較對比（2022-2024 年）

主要企業簡介

• Illumina, Inc.（USA）
• QIAGEN NV（Netherlands）
• NeoGenomics, Inc.（USA）
• Thermo Fisher Scientific（USA）
• Roche Diagnostics（Switzerland）
• Guardant Health, Inc.（USA）
• Foundation Medicine, Inc.（USA）
• Sysmex Corporation（Japan）
• Becton, Dickinson and Company（BD）（USA）
• F. Hoffmann-La Roche Ltd.（Switzerland）
• Merck & Co., Inc.（USA）
• Pfizer Inc.（USA）
• Novartis AG（Switzerland）
• AstraZeneca（UK）
• Bristol-Myers Squibb Company（USA）
• Johnson & Johnson（USA）
• Danaher Corporation（USA）
• Abbott Laboratories（USA）

結論和建議

Global Cancer Tumor Profiling Market size was valued at USD 12.1 billion in 2023 and is poised to grow from USD 13.44 billion in 2024 to USD 31.2 billion by 2032, growing at a CAGR of 11.1% during the forecast period (2025-2032).

The global cancer detection and treatment market is bolstered by the rising prevalence of cancer and the increasing utilization of biomarkers in tumor profiling. Enhanced research funding and technological advancements are fueling growth in the cancer and tumor profiling sectors. Furthermore, the trend towards personalized medicine and point-of-care diagnostics is anticipated to create substantial opportunities for market participants in the coming years. While the COVID-19 pandemic initially disrupted cancer testing and diagnosis, the overall market remained resilient. During the forecast period, cancer/tumor profiling segments encompassing genomics, proteomics, epigenetics, and metabolomics are expected to thrive, with genomics projected to achieve the highest CAGR of 19.7%, driving innovations in understanding gene abnormalities connected to cancer resilience and progression.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Cancer Tumor Profiling market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Cancer Tumor Profiling Market Segments Analysis

Global Cancer Tumor Profiling Market is segmented by Cancer type, Biomarker type, Technology, Technique, Application and region. Based on Cancer type, the market is segmented into Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer. Based on Biomarker type, the market is segmented into Genomic Biomarker and Protein Biomarker. Based on Technology, the market is segmented into Immunoassays, Next-Generation Sequencing, Polymerase Chain Reaction, Mass Spectrometry, In-Situ Hybridization, Microarrays and Others. Based on Technique, the market is segmented into Genomics, Proteomics, Metabolomics and Epigenetics. Based on Application, the market is segmented into Research, Biomarker Discovery, Personalized Medicine, Clinical Application, Diagnostics, Prognostics, Screening and Treatment and Monitoring. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Cancer Tumor Profiling Market

The rise in cancer cases significantly drives the growth of the global cancer tumor profiling market. This increase in cancer prevalence is influenced by several factors, including an aging population, population growth, and shifts in the incidence of various cancer-causing elements. As cancer remains a complex and pervasive disease with various underlying causes, the growing burden necessitates advanced profiling techniques to enhance diagnosis, treatment, and patient outcomes. The urgent need for tailored therapeutic approaches arises from this complex landscape, solidifying the importance of cancer tumor profiling in addressing the ongoing challenges posed by the escalating incidence of cancer worldwide.

Restraints in the Global Cancer Tumor Profiling Market

Challenges related to technical issues in sample collection and storage present significant obstacles to the growth of the global cancer tumor profiling market. While personalized medicine is rapidly evolving and transforming disease identification, classification, and treatment in healthcare, these advancements are hampered by inconsistent sample management processes. As this more tailored approach to treatment becomes integrated into standard clinical practices, its impact on oncology is undeniable. However, the risks associated with sample handling and storage could impede the progress and acceptance of these innovations, ultimately affecting the overall development of the cancer tumor profiling sector.

Market Trends of the Global Cancer Tumor Profiling Market

The Global Cancer Tumor Profiling market is witnessing a significant trend driven by the integration of omics data and advancements in liquid biopsy technologies, projected to exhibit the highest CAGR during the forecast period. This shift aligns with the rising prominence of personalized medicine, transforming disease diagnosis, classification, and treatment. As tailored therapies become a standard in clinical practice, particularly within oncology, the market is evolving to accommodate innovative diagnostic tools and targeted treatment approaches. The convergence of advanced analytics and molecular profiling is revolutionizing cancer care, fostering early detection and improved patient outcomes across the globe.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Cancer Tumor Profiling Market Size by Cancer type & CAGR (2025-2032)

• Market Overview
• Breast Cancer
• Lung Cancer
• Colorectal Cancer
• Prostate Cancer
• Melanoma Cancer
• Other Cancer

Global Cancer Tumor Profiling Market Size by Biomarker type & CAGR (2025-2032)

• Market Overview
• Genomic Biomarker
• Protein Biomarker

Global Cancer Tumor Profiling Market Size by Technology & CAGR (2025-2032)

• Market Overview
• Immunoassays
• Next-Generation Sequencing
• Polymerase Chain Reaction
• Mass Spectrometry
• In-Situ Hybridization
• Microarrays
• Others

Global Cancer Tumor Profiling Market Size by Technique & CAGR (2025-2032)

• Market Overview
• Genomics
• Proteomics
• Metabolomics
• Epigenetics

Global Cancer Tumor Profiling Market Size by Application & CAGR (2025-2032)

• Market Overview
• Research
• Biomarker Discovery
• Personalized Medicine
• Clinical Application
• Diagnostics
• Prognostics
• Screening
• Treatment and Monitoring

Global Cancer Tumor Profiling Market Size & CAGR (2025-2032)

• North America (Cancer type, Biomarker type, Technology, Technique, Application)
  • US
  • Canada
• Europe (Cancer type, Biomarker type, Technology, Technique, Application)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Cancer type, Biomarker type, Technology, Technique, Application)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Cancer type, Biomarker type, Technology, Technique, Application)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Cancer type, Biomarker type, Technology, Technique, Application)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Illumina, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• QIAGEN N.V. (Netherlands)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• NeoGenomics, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche Diagnostics (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Guardant Health, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Foundation Medicine, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sysmex Corporation (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Becton, Dickinson and Company (BD) (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd. (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Danaher Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations